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KC
 
 
 
 plays an essential role in activation of mature T
cells via stimulation of AP-1 and NF-
 
 
 
B, and is known
to selectively translocate to the immunological synapse
in antigen-stimulated T cells. Recently, we reported that a
Vav/Rac pathway which depends on actin cytoskeleton
reorganization mediates selective recruitment of PKC
 
 
 
 to
the membrane or cytoskeleton and its catalytic activation by
anti-CD3/CD28 costimulation. Because this pathway acted
selectively on PKC
 
 
 
, we addressed here the question of
whether the translocation and activation of PKC
 
 
 
 in T cells is
regulated by a unique pathway distinct from the conventional
mechanism for PKC activation, i.e., PLC-mediated production
of DAG. Using three independent approaches, i.e., a selective
PLC inhibitor, a PLC
 
 
 
1-deﬁcient T cell line, or a dominant
P
 
negative PLC
 
 
 
1 mutant, we demonstrate that CD3/CD28-
induced membrane recruitment and COOH-terminal
phosphorylation of PKC
 
 
 
 are largely independent of PLC. In
contrast, the same inhibitory strategies blocked the membrane
translocation of PKC
 
 
 
. Membrane or lipid raft recruitment
of PKC
 
 
 
 (but not PKC
 
 
 
) was absent in T cells treated with
phosphatidylinositol 3-kinase (PI3-K) inhibitors or in Vav-
deﬁcient T cells, and was enhanced by constitutively active
PI3-K. 3-phosphoinositide-dependent kinase-1 (PDK1) also
upregulated the membrane translocation of PKC
 
 
 
, but did
not associate with it. These results provide evidence that a
nonconventional PI3-K– and Vav-dependent pathway
mediates the selective membrane recruitment and, possibly,
activation of PKC
 
 
 
 in T cells.
 
Introduction
 
Members of the PKC family play an important role in T
cell  activation (Altman et al., 1990). T cells express several
members of the PKC family, but the relative contribution of
distinct T cell–expressed PKC enzymes to T cell receptor
(TCR)*/CD28-initiated signaling cascade is not well under-
stood. However, recent work revealed that at least one Ca
 
2
 
 
 
-
independent PKC, PKC
 
 
 
, which is selectively expressed in
T cells, muscle, and a few other tissues (Baier et al., 1993),
plays an important role in mature T cell activation (Altman
et al., 2000; Isakov and Altman, 2002). Thus, PKC
 
 
 
 acti-
vates AP-1 (Baier-Bitterlich et al., 1996) and NF-
 
 
 
B
(Coudronniere et al., 2000; Lin et al., 2000) and, accord-
ingly, receptor-induced AP-1 and NF-
 
 
 
B activation is
blocked in peripheral T cells from PKC
 
 
 
 knockout mice
(Sun et al., 2000). Second, engagement of antigen-specific T
cells by antigen-presenting cells (APCs) leads to a rapid,
stable, and high-stoichiometry localization of PKC
 
 
 
, but not
other T cell-expressed PKCs, to the T cell-APC contact site
(Monks et al., 1997). This contact site has recently been
termed the supramolecular activation complex (SMAC)
(Monks et al., 1998) or the immunological synapse (IS)
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(Grakoui et al., 1999). This clustering correlates with the
catalytic activation of PKC
 
 
 
, and it only occurs upon pro-
ductive activation of T cells (Monks et al., 1997). PKC
 
 
 
 also
positively regulates expression of the activation antigen,
CD69, which is expressed in subsets of developing thy-
mocytes and in activated T cells (Sun et al., 2000; Villalba et
al., 2000a).
The selective mechanism that recruits PKC
 
 
 
 to the
SMAC/IS during antigen stimulation remains elusive. In this
regard, we found recently that Vav and Rac selectively pro-
mote the membrane and cytoskeleton translocation of
PKC
 
 
 
, and mediate its enzymatic activation by CD3/CD28
costimulation in a process that depends on actin cytoskeleton
reorganization (Villalba et al., 2000a). A similar pathway me-
diates the antigen-induced translocation of PKC
 
 
 
 into lipid
rafts (Bi et al., 2001; Villalba et al., 2001). Similarly, recent
reports indicate functional cooperation between Vav and
PKC
 
 
 
 in several T cell signaling pathways (Dienz et al.,
2000; Hehner et al., 2000; Moller et al., 2001) and with the
finding that Vav is essential for actin polymerization and
TCR cap formation after TCR/CD3 ligation (Fischer et al.,
1998; Holsinger et al., 1998; Wülfing et al., 2000). Because
this effect was specific for PKC
 
 
 
 (Villalba et al., 2000a), we
hypothesized that it may represent a novel mechanism,
which is independent on the conventional PKC activation
pathway mediated by phospholipase C-
 
 
 
1 (PLC
 
 
 
1). In this
pathway, TCR-mediated tyrosine phosphorylation and sub-
sequent activation of PLC
 
 
 
1 (Granja et al., 1991; Park et al.,
1991; Secrist et al., 1991; Weiss et al., 1991) lead to hydroly-
sis of inositol phospholipids and production of the second
messenger, DAG. Membrane-associated DAG is an essential
cofactor that binds, recruits, and subsequently activates
Figure 1.  PKC  membrane translocation is independent of PLC 
activity. (A) Jurkat T cells (10
6) were stimulated with anti-CD3 plus 
anti-CD28 antibodies for 5 min. Aliquots of the cells were 
preincubated for 1 h with U73122 (10  M) or with PP2 (10  M). 
Cytosol (C), membrane (M), and detergent-insoluble (I) fractions 
were prepared, identical cell equivalents were resolved by SDS-PAGE, 
and the expression of PKC  and PKC  in each fraction was 
determined by immunoblotting with specific antibodies. (B) Activated 
human peripheral blood T cells (5   10
6) were deprived of anti-CD3 
antibody for 36 h, and then restimulated with anti-CD3 plus anti-
CD28 antibodies for 10 min. Aliquots of the cells were preincu-
bated for one hr with U73122 (10  M) or LY294002 (50  M). 
Subcellular fractions were prepared and analyzed as in A. (C) J. 1 
(a PLC 1-deficient Jurkat cell line) or J. 1.WT-2 (PLC 1-reconstituted 
J. 1) cells were stimulated and analyzed as in A. These results are representative of three similar experiments. The membrane-to-cytosol 
(M/C) ratio of PKC expression in each group is displayed. In A, B, and C, the numbers above the autoradiograms represent the percentage 
of PKC  or -  present in each fraction (C   M   I   100% for each group of cells), as determined by NIH Image scanning densitometry. 
(D) PKC  translocation to lipid rafts is present in PLC 1-deficient Jurkat cells. J. 1 or J. 1.WT-2 (20   10
6) were left unstimulated (ns) or 
stimulated with anti-CD3 plus anti-CD28 antibodies. The cells were lysed and the detergent-insoluble fractions were separated from the 
soluble fractions. The distribution of PKC  in each fraction was determined by immunoblotting with a specific antibody. (E) The same blot 
was stripped and blotted with a PLC 1-specific antibody. 
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Ca
 
2
 
 
 
-dependent conventional PKCs (cPKCs) and Ca
 
2
 
 
 
-inde-
pendent novel PKCs (nPKCs) in the plasma membrane
(Nishizuka, 1995; Irvin et al., 2000; Zhang et al., 2000).
PLC
 
 
 
1 plays an important role in T cell activation, as T cells
expressing a LAT mutant, which cannot recruit and activate
PLC
 
 
 
1, are deficient in several downstream signaling events,
including Ca
 
2
 
 
 
 mobilization and activation of the Ras/ERK
pathway and NFAT (Irvin et al., 2000; Zhang et al., 2000).
Similarly, a PLC
 
 
 
1-deficient T cell line was recently found
to display severe activation defects (Irvin et al., 2000).
In the present work, we examined the role of PLC
 
 
 
1 in
the membrane and lipid raft recruitment of PKC
 
 
 
 and its
catalytic activation in T cells. Using three independent ap-
proaches to deplete or inhibit cellular PLC
 
 
 
1 activity, we
demonstrate that the membrane recruitment and activation
of PKC
 
 
 
 (but not PKC
 
 
 
) are independent of PLC
 
 
 
1. We
further show that this mechanism involves Vav, phosphati-
dylinositol 3-kinase (PI3-K), and, indirectly, 3-phospho-
inositide-dependent kinase-1 (PDK1). These results support
the existence of a novel mechanism, which plays a role in the
selective TCR-induced activation of PKC
 
 
 
 and, potentially,
its recruitment to the T cell synapse.
 
Results
 
PLC-inhibiting strategies fail to block membrane 
recruitment and phosphorylation of PKC
 
 
 
To determine whether the reported Vav/Rac-mediated re-
cruitment of PKC
 
 
 
 to the T cell membrane/cytoskeleton
and its activation (Villalba et al., 2000a) are strictly depen-
dent on activation of PLC
 
 
 
1, we initially examined the ef-
fects of U73122 on the anti–CD3/CD28-induced transloca-
tion of PKC
 
 
 
 (or, for comparison, PKC
 
 
 
). This compound
inhibits agonist-induced activation of PLC and the subse-
quent hydrolysis of inositol phospholipids in different cell
types (Wang et al., 1994), including in TCR-stimulated T
cells (Vassilopoulos et al., 1995). Combined anti-CD3/
CD28 stimulation induced translocation of both PKC en-
zymes to the membrane, as evidenced by the approximately
twofold increase in membrane expression of immunoreac-
tive PKC (Fig. 1 A). As expected, U73122 pretreatment
abolished the membrane translocation of PKC
 
 
 
 and, in fact,
even reduced its membrane expression below the basal level
in unstimulated cells (Fig. 1 A). However, surprisingly,
U73122 only minimally reduced the membrane transloca-
tion of PKC
 
 
 
. As an additional control for the effectiveness
of U71322 pretreatment, it also blocked the increase in in-
tracellular calcium concentration induced by an anti-CD3
antibody (unpublished data). Conversely, PP2, an inhibitor
specific for Src-family kinases, prevented the membrane
translocation of PKC
 
 
 
, but had only a minimal effect on
PKC
 
 
 
 translocation.
Similar results were obtained using activated human
peripheral blood T cells. Thus, U73122 inhibited the
anti–CD3/CD28-induced PKC
 
 
 
 translocation, but had
no significant effect on PKC
 
 
 
 translocation (Fig. 1 B).
On the other hand, the PI3-K inhibitors LY294002
(Fig. 1 B) or wortmannin (unpublished data) essentially
blocked the translocation of PKC
 
 
 
, but only had a mini-
mal effect on PKC
 
 
 
.
Next, we compared the receptor-induced membrane
translocation of PKC
 
 
 
 or PKC
 
 
 
 in J.
 
 
 
1, a PLC
 
 
 
1-deficient
cell line, versus J.
 
 
 
1.WT-2, a PLC
 
 
 
1-reconstituted cell line
derived from this mutant (Irvin et al., 2000). In the J.
 
 
 
1
cells, anti-CD3 plus anti-CD28 stimulation still induced
PKC
 
 
 
, but not PKC
 
 
 
, translocation (Fig. 1 C). Reconstitu-
tion of J. 1 cells with wild-type PLC 1 (J. 1.WT-2) re-
stored PKC  translocation, with a minimal effect on PKC 
translocation. Calculation of the PKC membrane/cytosol
expression ratio for each group of cells makes it evident that:
(a) Stimulation increases the relative membrane expression
of both PKC  and   in the PLC 1-reconstituted cells; and
(b) In the PLC 1-deficient cells, stimulation still increases
the relative membrane expression of PKC , but not PKC .
Anti-CD3/CD28 stimulation induces a Vav/Rac-depen-
dent (Villalba et al., 2001) PKC  translocation to membrane
lipid rafts, which also localize at the IS (Bi et al., 2001).
Therefore, we wished to determine whether this lipid raft
translocation of PKC  requires PLC 1. Detergent-insoluble
glycolipid (DIG) or soluble fractions were isolated from
unstimulated or anti–CD3/CD28-stimulated J. 1 and
J. 1.WT-2 cells, and PKC  expression in different fractions
was examined by immunoblotting. As shown previously (Bi
et al., 2001; Villalba et al., 2001), stimulation induced
PKC  translocation to the DIG-containing fractions (lipid
rafts) in both cell lines (Fig. 1 D), albeit the distribution pat-
tern of PKC  among the relevant fractions (2–4) differed be-
tween the two cell lines. Nevertheless, the overall amount of
PKC  in fractions 2–4 was higher in J. 1.WT-2 cells when
compared with the PLC 1-deficient J. 1 cells, suggesting
some role for PLC 1. The same fractions were probed in
parallel with a PLC 1-specific antibody. As expected, the
J. 1 cells did not express detectable amounts of PLC 1 and,
in agreement with previous results (Zhang et al., 2000),
stimulation induced translocation of PLC 1 to the lipid rafts
in the reconstituted (PLC 1 wt-2) cells (Fig. 1 E).
Activation of PKC enzymes is associated with their auto-
or heterophosphorylation, events that regulate the enzymatic
activity (Newton, 1997; Parekh et al., 2000). Although the
regulation of PKC  localization and/or activity by phos-
phorylation has not been analyzed in detail, a recent study
indicated that an antibody specific for phosphorylated Thr-
538 in the activation loop of PKC  reacted specifically with
the active, membrane-localized fraction of PKC  (Bauer et
al., 2001). We used another antibody specific for Ser-695 in
the COOH-terminal tail of PKC , which is a potential au-
tophosphorylation (Keranen et al., 1995) or heterophosphor-
ylation (Ziegler et al., 1999; Parekh et al., 2000) site based
on its homology with other PKC enzymes in order to assess
the role of PLC 1 in PKC phosphorylation. This site has
very recently been implicated as a positive regulatory site in
PKC  (Liu et al., 2002). As expected, this antibody did not
recognize PKC  in unstimulated T cells, even though PKC 
was readily detected by a PKC -specific antibody (Fig. 2,
two top panels). Anti-CD3 plus anti-CD28 stimulation in-
duced the expected translocation of PKC  to the insoluble
fraction, which represents the pooled membranes and cyto-
skeleton. Unlike the PKC -specific antibody, the phos-
pho-PKC –specific antibody only recognized PKC  from
activated cells, which was exclusively associated with the in-256 The Journal of Cell Biology | Volume 157, Number 2, 2002
soluble fraction. Importantly, pretreatment of the cells with
a selective PLC inhibitor (U73122, two middle panels) or its
nonfunctional analog (U73343, two bottom panels) had no
significant effect on the induction and membrane transloca-
tion of phospho-PKC  (Fig. 2).
PLC 1 is not required for Vav-dependent membrane 
clustering of PKC 
Based on recent findings that a functional interaction be-
tween the Vav/Rac pathway and PKC  is required for T cell
activation (Dienz et al., 2000; Hehner et al., 2000; Villalba et
al., 2000a; Moller et al., 2001), we considered the Vav/Rac
pathway as a candidate for a selective PLC 1-independent
mechanism that recruits PKC  to the membrane. Therefore,
we next used a dominant negative PLC 1 mutant (PLCz),
which was previously found to inhibit PLC 1-dependent
functions in various cells (Chen et al., 1996), to investigate
whether the Vav-induced PKC  translocation depends on
PLC 1. Cells were cotransfected with the regulatory domain
of PKC  fused to the NH2 terminus of green fluorescent pro-
tein (GFP) (Villalba et al., 2000a) plus combinations of
empty vector, PLCz, and/or wild-type Vav. The intracellular
localization of GFP (PKC ) and polymerized actin (F-actin)
were analyzed by confocal microscopy (Fig. 3 A)
In agreement with our previous results (Villalba et al.,
2000a), either Vav overexpression or anti-CD3 stimulation
induced in parallel PKC  translocation to the membrane
and F-actin accumulation, and these effects were further en-
Figure 2.  Inhibition of PLC does not block PKC  COOH-terminal 
phosphorylation. Jurkat T cells (2   10
6) were left unstimulated or 
stimulated with anti-CD3 plus anti-CD28 antibodies (1  g/ml each) 
for the indicated times. Cell aliquots were preincubated for 1 h with 
U73122 or U73343 (10  M). Cytosol and insoluble fractions were 
prepared, resolved by SDS-PAGE, and blotted with anti-phospho-
PKC  (p-PKC ) or anti-PKC  antibodies. The insoluble fraction
represents the combined membrane and cytoskeleton fractions, 
which was not further fractionated in order to minimize 
dephosphorylation of p-PKC .
Figure 3.  Vav-induced PKC  transloca-
tion does not depend on PLC 1 activity. 
(A) Jurkat-TAg cells were cotransfected 
with the indicated combinations of 
empty vector (Vector) or Vav (5  g 
each), and/or dominant negative PLC 1 
(PLCz; 15  g) together with a PKC  
regulatory domain-GFP expression 
plasmid (5  g). After 2 d, cells were 
fixed and GFP localization was analyzed 
by confocal imaging. A portion of the 
cells in each group was stimulated for 
the final 10 min of culture with anti-CD3 
(1  g/ml). PKC -GFP (green) and F-actin 
(red) localization was analyzed by 
confocal microscopy. The right column 
panels in the resting or stimulated groups represent a threefold enlargement of a single cell marked with an arrow in the middle column panels. 
The bars in the lower right micrograph correspond to 20  . (B) PLCz blocks Vav- or anti-CD3–induced NFAT activation. Jurkat-TAg cells 
(10   10
6) were transfected with the indicated combinations of Vav (5  g) and/or PLCz (15  g) in the presence of NFAT-Luc (5  g) and 
 -Gal (1.5  g). Cells were left unstimulated or stimulated for the final 6 h of culture with anti-CD3 or with PMA (100 ng/ml) plus ionomycin 
(1  g/ml). Luciferase activity was determined after 48 h of culture, and normalized to the activity of a cotransfected  -galactosidase plasmid. 
Data represent percentage of the response induced by PMA plus ionomycin, and are average   standard deviation of two experiments 
performed in duplicate.Vav/PI3-K–dependent PKC  activation in T cells | Villalba et al. 257
hanced in anti-CD3 stimulated, Vav-transfected cells. Thus,
in the latter case, a very pronounced actin capping and
PKC  colocalization, as well as F-actin–enriched, lamelipo-
dia-like structures were observed. Coexpression of PLCz did
not reduce the anti-CD3–induced membrane translocation
of GFP-PKC , nor did it affect the membrane localization
of GFP-PKC  (or its colocalization with F-actin) in cells
that were additionally transfected with Vav, and were either
unstimulated or stimulated. As a control for the effectiveness
of the dominant negative PLC 1 mutant, its overexpression
under similar conditions blocked the anti-CD3– and/or
Vav-induced nuclear factor of activated T cells (NFAT) acti-
vation (Fig. 3 B). This dichotomy is consistent with the no-
tion that Vav activates multiple pathways mediated by
different effectors (Collins et al., 1997; Bustelo, 2000;
Krawczyk et al., 2000; Villalba et al., 2000b), of which only
some may depend on intact PLC 1/Ca
2  signals. Taken to-
gether, the results shown above (Figs. 1–3) suggest that
CD3/CD28 engagement causes membrane translocation of
PKC  via a nonconventional pathway, which appears to be,
at least in part, PLC 1-independent.
Defective membrane translocation of PKC  in
Vav-deficient primary T cells
Next, we decided to study the components of the unique
pathway involved in the membrane translocation of PKC .
First, we examined the role of Vav by comparing T cells
from wild-type versus Vav-deficient T cells (Fig. 4). F-actin
localization was determined in parallel. In order to expand
the T cell population from the vav
 /  mice, their lymph
node cells were activated with an anti-CD3 mAb in the pres-
ence of IL-2, and then rested prior to restimulation. In T
cells derived from vav
 /  mice, combined CD3/CD28 en-
gagement induced actin polymerization, with a tendency of
F-actin to polarize in a cap-like structure in a fraction of the
cells. In agreement with previous results (Fischer et al.,
1998; Holsinger et al., 1998), this outcome was clearly
reduced in stimulated T cells derived from vav
 /  mice (Fig.
4 A).
Parallel analysis of endogenous PKC  localization demon-
strated that CD3/CD28 engagement induced membrane
translocation of PKC  in wild-type T cells. This membrane
expression was not uniform, but rather restricted to certain
parts of the membrane where the endogenous PKC  was
found in one or more cap-like structure (Fig. 4 A). An over-
lay of the two images clearly demonstrated substantial colo-
calization of F-actin and PKC  in the stimulated T cells.
This colocalization was observed in a larger fraction of the
cells by comparison with the unstimulated cells. In contrast,
the stimulated T cells from vav
 /  mice did not differ signif-
icantly from their unstimulated counterparts with regard to
PKC  localization. Although some colocalization of F-actin
and PKC  was observed in these cells, it was markedly less
pronounced than in the Vav-expressing T cells. This result is
in agreement with our earlier finding that a dominant nega-
tive Vav mutant blocked the anti-CD3/CD28–induced
Figure 4.  Vav is required for PKC  
translocation to the cap-like membrane 
structures. (A) Lymph node–derived T 
cells from Vav
 /  or wild type mice were 
activated with anti-CD3 for 5 d and 
rested for two additional days. The cells 
were then plated over poly-L-lysine–
coated glass slides and left unstimulated 
(resting) or stimulated for 10 min with 
anti-CD3 plus anti-CD28 antibodies. The 
cells were fixed and analyzed for PKC  
(red) or F-actin (green) localization. The 
overlay images are also shown. Arrow-
heads indicate T cells with capped PKC  
and F-actin. One cell labeled with an 
arrow in each left panel is magnified 
threefold in the right panels. The bars 
in the lower right micrograph correspond 
to 10  . (B) Quantitation of the results 
displayed in A. These results represent 
the average of two experiments, in which 
at least 100 cells were evaluated for 
PKC  or F-actin membrane clustering.258 The Journal of Cell Biology | Volume 157, Number 2, 2002
membrane translocation of PKC  (Villalba et al., 2000a).
Quantitation of these results clearly demonstrates the defect
in both PKC  and F-actin capping in the Vav-deficient T
cells (Fig. 4 B).
The role of PI3-K in Vav-mediated membrane 
translocation of PKC 
PI3-K–generated lipid products activate Vav and recruit it
to the membrane by binding to its pleckstrin-homology
(PH) domain (Han et al., 1998). Consistent with this find-
ing, a PI3-K inhibitor blocked the membrane translocation
of PKC  in peripheral blood T cells (Fig. 1 B). Together,
these findings suggest a role for PI3-K in activating the Vav
pathway involved in PKC  membrane translocation. To ad-
dress this potential role, we examined the effect of a trans-
fected membrane-targeted (constitutively active) p110 plas-
mid or a PI3-K inhibitor on the membrane and cytoskeleton
translocation of cotransfected PKC  in Jurkat-TAg cells. As
a positive control, we cotransfected another group of cells
with Vav, which induces PKC  translocation to these sub-
cellular compartments (Villalba et al., 2000a).
In empty vector-transfected cells, anti-CD3 stimulation
induced membrane translocation of PKC , which was re-
duced by LY294002 pretreatment (Fig. 5 A, top). Similar to
Vav, p110 overexpression also induced PKC  translocation
to the membrane as well as the cytoskeleton fractions in un-
stimulated cells, but no significant cooperation between Vav
and p110 was observed; either Vav or p110 enhanced the
ability of an anti-CD3 antibody to translocate PKC  (Fig. 5
B). Expression of p110, as well as anti-CD3 stimulation,
also enhanced the membrane and cytoskeleton translocation
of Vav (Fig. 5 A, two bottom panels). The PI3-K inhibitor
LY294002 markedly inhibited both the p110- and Vav-
induced PKC  translocation. However, it was less effective
in Vav- plus p110-cotransfected cells, possibly reflecting the
strong activating effect of this combined transfection and/or
sufficient tyrosine kinase-mediated and PI3-K-independent
Vav activation under these conditions.
Additional experiments demonstrated that a dominant
negative Vav mutant, Vav PH (Villalba et al., 2000a),
blocked the membrane and cytoskeleton translocation of
PKC  induced by p110 or anti-CD3, and even reduced the
basal expression of PKC  in these compartments in unstim-
ulated cells (Fig. 5 B). The specificity of this effect vis-à-vis
p110 and receptor (CD3) stimulation is evident from the
finding that Vav PH had no effect on PMA-induced PKC 
translocation. Of interest, the majority of the transfected
Vav PH protein localized to the cytoskeleton, and this lo-
calization was not affected by p110 coexpression (Fig. 5 B,
two bottom panels). This finding suggests that Vav PH ex-
erts its dominant negative effect by competing with endoge-
nous Vav for binding to potential Vav targets in the cyto-
skeleton compartment, where Vav is translocated following
activation (Fig. 5 A). In addition, combined anti-CD3/
CD28–induced PKC  translocation into the lipid rafts was
also blocked by wortmannin and LY294002 (unpublished
data). Taken together, these data lend further support for
the notion that PI3-K functions upstream of Vav to regulate
the membrane and lipid raft translocation of PKC  (Villalba
et al., 2000a, 2001). This pathway appears to be functional
in Jurkat (Fig. 5) as well as normal peripheral blood T cells
(Fig. 1 B).
PDK1 is indirectly involved in the membrane 
translocation of PKC 
PDK1 associates with, and is responsible for, activation loop
phosphorylation of different PKC enzymes (Chou et al.,
1998; Dutil et al., 1998; Le Good et al., 1998; Balendran et
al., 2000; Dutil and Newton, 2000; Gao et al., 2001).
PDK1 and PKC need to be corecruited to the membrane
through interaction with their respective membrane-local-
ized allosteric activators in order for this phosphorylation to
be efficient (Chou et al., 1998; Parekh et al., 2000; Toker
and Newton, 2000; Sonnenburg et al., 2001). Calphostin C,
which selectively blocks the allosteric activation of PKC by
DAG, also inhibits serum-induced activation loop phos-
phorylation, as do PI3-K inhibitors (Parekh et al., 1999).
Figure 5.  Vav-mediated PKC  translocation depends on PI3-K. 
(A) Jurkat-TAg T cells were transiently cotransfected with an Xpress-
tagged PKC  expression vector plus c-Myc–tagged Vav or constitu-
tively active PI3-K (CD2p110) expression vectors. After 40 h, the 
cells were left unstimulated or stimulated for 8 min with an anti-CD3 
antibody (Jurkat-TAg cells do not express CD28) in the absence or 
presence of pretreatment with LY294002 (50  M; 45 min). Subcellular 
fractionation was performed as in Fig. 1. The transfected PKC  and 
Vav were detected by anti-Xpress and anti–c-Myc immunoblotting, 
respectively. (B) Jurkat-Tag T cells were transfected with the indicated 
vectors, left unstimulated or stimulated for 8 min with anti-CD3 or 
PMA (100 ng/ml), and analyzed as in A.Vav/PI3-K–dependent PKC  activation in T cells | Villalba et al. 259
These findings suggested an alternative mechanism for the
membrane recruitment of PKC , i.e., its association with
PDK1, which, by virtue of its PH domain, may localize
PKC  to the membrane. Therefore, we examined the rela-
tive localization of PDK1 and PKC  in unstimulated or
TCR-stimulated T cells.
When Jurkat T cells were stimulated with a combination
of anti-CD3 plus -CD28 antibodies (or with PMA), endog-
enous PKC  was clearly translocated to the membrane frac-
tion; however, under the same conditions we could not de-
tect similar translocation of endogenous PDK1 (Fig. 6 A),
indicating that in T cells, PDK1 intracellular localization is
not regulated by TCR/CD28 stimulation. To assess more
directly whether PDK1 can influence the translocation of
PKC , we cotransfected Jurkat-TAg cells with PKC  plus
PDK1 expression vectors. PDK1 coexpression enhanced the
membrane and cytoskeleton translocation of PKC , and this
effect was only partially sensitive to a PI3-K inhibitor (Fig.
6, B and C). Interestingly, this enhanced PDK1-induced
translocation of PKC  was largely reversed by coexpression
of the dominant negative ( PH) Vav mutant. Even under
these overexpression conditions, no PDK1 was detected in
the membrane and cytoskeletal fractions of the stimulated
cells (Fig. 6 C). In other, functional assays we found that co-
expression of PDK1 with PKC  did not enhanced the
PKC -induced activation of NF- B and AP-1 reporter
genes (unpublished data). These results suggest that, al-
though PDK1 may be involved in the maturation (perhaps
via activation loop phosphorylation; Bauer et al., 2001) of
PKC  in a similar manner to other PKC enzymes (Chou et
al., 1998; Dutil et al., 1998; Le Good et al., 1998; Dutil and
Newton, 2000; Toker and Newton, 2000), it does not di-
rectly translocate PKC  to the membrane by associating
with it in T cells.
Discussion
Membrane translocation and subsequent activation of
cPKCs and nPKCs requires their conserved C1 domain,
which binds the second messenger DAG formed in the inner
leaflet of the plasma membrane as a result of PLC activation
by various receptors (or phorbol ester pharmacophores). The
importance of this event was demonstrated by findings that
mutations in the C1 domain of several members of the PKC
family, e.g. PKC  (a cPKC) and PKC  (a nPKC), abolish
DAG/PMA binding in vitro and/or PMA-mediated mem-
brane translocation (Szallasi et al., 1996; Medkova and Cho,
1999). Although DAG-mediated membrane recruitment
could play a role in the translocation and activation of
PKC  as well, it is difficult to explain how DAG binding
alone, which is relatively nonselective, could account for the
highly specific recruitment of PKC  to the core region of
the SMAC (cSMAC) or the IS. This high degree of selectiv-
ity implicates an additional undefined mechanism that ei-
ther cooperates with PLC-generated DAG, or acts exclu-
sively, to recruit PKC  to, and activate it in, specific
membrane microdomains, i.e., the cSMAC (Monks et al.,
1997, 1998) or lipid rafts (Bi et al., 2001; Villalba et al.,
2001). This notion is supported by our earlier work demon-
strating that a Vav/Rac pathway, which involves actin cy-
toskeleton reorganization, mediates the membrane recruit-
ment and activation of PKC  (but not, e.g., PKC ) in
response to TCR/CD28 engagement (Villalba et al., 2000a).
In this study we sought to further define components of
the selective pathway responsible for PKC  membrane re-
cruitment and, furthermore, the relative importance of the
conventional PLC/DAG-mediated pathway in this event.
First, we used three distinct approaches, i.e., a pharmacolog-
ical PLC inhibitor, a PLC 1-deficient T cell line, and a
dominant negative PLC 1 mutant to examine the role of
PLC by comparing the behavior of PKC  to that of a repre-
sentative T cell–expressed cPKC, PKC . Each of these
PLC-inhibiting strategies inhibited the membrane recruit-
ment and/or activation of PKC , but had, at best, a small
effect on PKC . In addition, we demonstrate that, like Vav
Figure 6.  PKC  translocation is indirectly mediated by PDK1. (A) 
Jurkat E6.1 cells (10
6) were stimulated with anti-CD3 plus anti-CD28 
antibodies or PMA for 8 min. Subcellular fractions were prepared 
and analyzed for endogenous PKC  and PDK1 expression by
immunoblotting with specific antibodies. (B) Jurkat-TAg cells were 
transiently cotransfected with an Xpress-tagged PKC  expression 
vector plus c-Myc–tagged PDK1 or PDK1 plus Vav PH. 40 h later, 
the cells were left unstimulated, or stimulated with anti-CD3 anti-
body. A fraction of the stimulated cells was pretreated for 
LY294002. Subcellular fractionation and immunoblotting were 
performed as in Fig. 5 and transfected PKC  was detected by 
anti-Xpress immunoblotting. (C) Jurkat-TAg cells were transfected 
as in (B), and the cells were left unstimulated or stimulated with 
anti-CD3 or PMA. Transfected PKC  and PDK1 expression in 
different fractions was determined by immunoblotting with the 
corresponding tag-specific antibodies.260 The Journal of Cell Biology | Volume 157, Number 2, 2002
(Villalba et al., 2000a), constitutively active PI3-K promotes
membrane recruitment of PKC , and that a PI3-K inhibitor
blocks this event. Furthermore, we show that a dominant
negative Vav mutant blocked PI3-K (p110)-induced PKC 
translocation, suggesting that PI3-K functions either up-
stream of, or in parallel to, Vav to mediate PKC  membrane
translocation. The finding that recruitment of PKC  to the
cap formed by TCR/CD28 stimulation is largely absent in
Vav-deficient T cells or is blocked by dominant negative
Vav mutants in Vav-expressing T cells reaffirms the impor-
tance of Vav in this event.
The requirement for both Vav and PI3-K in PKC  mem-
brane translocation and activation most likely reflects the
fact that Vav is a critical target for PI3-K in a single pathway
regulating PKC  activation in the IS. This putative mecha-
nism is consistent with the finding that Vav is activated by
PIP3 binding to its PH domain (Han et al., 1998), a process
that recruits Vav to the membrane and facilitates its catalytic
activation by regulatory tyrosine phosphorylation (Aghaza-
deh et al., 2000). The requirement of TCR/CD28 costimu-
lation for stable activation and membrane or lipid raft trans-
location of PKC  (Coudronniere et al., 2000; Bi et al.,
2001) could reflect this dual regulatory mechanism for Vav
activation. Thus, PI3-K is primarily stimulated by CD28 li-
gation (Rudd, 1996) and tyrosine kinases such as Lck and
ZAP-70 are targets for TCR signals (van Leeuwen and
Samelson, 1999; Kane et al., 2000). In this regard, CD28
has been shown to colocalize with PKC  at the IS (Monks et
al., 1998), and lipid rafts, which accumulate at the IS in an-
tigen-stimulated T cells (Bi et al., 2001), represent sites
where PIP2, the precursor of PIP3, is formed in the mem-
brane (Rozelle et al., 2000). Such a dual role for tyrosine ki-
nases and PI3-K in Vav stimulation leading to PKC  acti-
vation is also consistent with our findings that PKC 
membrane recruitment is inhibited by both Src family and
PI3-K inhibitors. Finally, the finding that Vav and constitu-
tively active PI3-K do not cooperate to enhance membrane
translocation of PKC  (Fig. 5) is also consistent with the no-
tion that PI3-K and Vav function in a single pathway. How-
ever, we cannot formally rule out the possibility that Vav
and PI3-K function in two independent pathways to pro-
mote PKC  translocation and activation.
Although PDK1 overexpression induced prominent trans-
location of PKC  to the membrane and to the cytoskeleton
(Fig. 6), it itself did not undergo detectable membrane
translocation upon T cell activation, even when overex-
pressed in T cells. These findings strongly suggest that direct
association of PKC  with PDK1 does not occur in stimu-
lated T cells and, therefore, most likely cannot account for
the inducible membrane translocation of PKC . Further-
more, if PDK1 associated with PKC , PDK1 overexpression
in the cytosol would be expected to retain PKC  in the cyto-
sol and, thus, inhibit its anti-CD3–induced translocation to
the membrane, but we actually observed the opposite result.
Thus, PDK1 may play an indirect role in the membrane
translocation of PKC , perhaps reflecting its ability to phos-
phorylate PKC  and induce its maturation, as demonstrated
for other members of the PKC family (Chou et al., 1998;
Dutil et al., 1998; Le Good et al., 1998; Dutil and Newton,
2000; Toker and Newton, 2000). This effect appeared to be
partially PI3-K–independent, consistent with a recent report
(Sonnenburg et al., 2001). However, the details of this indi-
rect effect remain to be determined. At any rate, our finding
that PDK1 does not increase PKC -induced NF- B or
AP-1 activity (unpublished data) indicates that PDK1-medi-
ated PKC  translocation is not sufficient to render it
functional. Finally, the ability of dominant negative Vav to
inhibit PDK1-induced PKC  translocation suggests that
Vav may function downstream of PDK1. However, the two
could function in separate pathways, a notion supported by
the finding that, unlike Vav (Dienz et al., 2000; Hehner et
al., 2000), PDK1 did not cooperate with PKC  to activate
NF- B (unpublished data).
Our results do not completely rule out a requirement for
DAG binding to the PKC  C1 domain in initiating its
membrane binding and activation. It is possible that some
residual level of basal DAG that remains even under condi-
tions of blocked PLC activity is sufficient to initiate PKC 
membrane binding. Albeit not sufficient for further recruit-
ment of PKC  to specific membrane compartments such as
the IS or lipid rafts, it may facilitate the interaction of PKC 
with membrane or cytoskeletal component required for
translocation of PKC  to the cSMAC and its full activation.
Such a component could be some membrane-localized pro-
tein kinase that transphosphorylates PKC  or an adapter/
scaffold protein that recruits it to specific membrane micro-
domains (Monks et al., 1997, 1998) or lipid rafts (Bi et al.,
2001; Villalba et al., 2001). However, even if such a cooper-
ative binding-activation mechanism exists, we still conclude
that, unlike other PKCs, activated PLC and its lipid second
messengers are not absolutely essential for PKC  IS translo-
cation and activation.
In summary, our study defines a Vav-, PI3-K– and, indi-
rectly PDK1-dependent pathway(s), which selectively regu-
lates the IS recruitment and activation of PKC  in T cells.
Thus, in addition to the conventional PLC/DAG-depen-
dent pathway, the TCR/CD28 receptor system governs at
least one additional pathway that positively regulates PKC
function. Ongoing studies will define in more detail the mo-
lecular basis of this novel pathway.
Materials and methods
Antibodies and reagents
Rabbit (C-18) or goat (C-19) anti-PKC , goat PDK1, and rabbit anti-PLC 1
polyclonal antibodies were obtained from Santa Cruz Biotechnology.
PKC - or  -specific mAbs were obtained from Transduction Laboratories.
The anti–human CD3 mAb (OKT3), was purified as previously described
(Villalba et al., 1999). The anti–human CD28 mAb was from Pharmingen.
The anti–mouse CD3 and CD28 mAbs were a gift from Dr. M. Croft
(La Jolla Institute for Allergy and Immunology, San Diego, CA). The anti–
human Vav mAb was from Upstate Biotechnology. Donkey anti–rabbit or
sheep anti–mouse IgG antibodies were obtained from Amersham Pharma-
cia Biotech. LY294002, wortmannin, PP2, U73122, and U73343 were ob-
tained from Calbiochem. All other reagents were obtained from Sigma-
Aldrich. Vav
 /  mice were a gift from Dr. V. Tybulewicz (National Institute
for Medical Research, London, UK) (Turner et al., 1997; Costello et al.,
1999). An anti–phospho-PKC  antibody was generated by immunizing
rabbits with a synthetic phosphopeptide corresponding to the sequence
surrounding pSer-695 of PKC . The homologous residue in other PKC en-
zymes is auto phosphorylated during activation of the enzyme (Keranen et
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Plasmids
The c-Myc–tagged Vav and Vav PH expression plasmids in the pEF vec-
tor, an expression vector encoding the regulatory domain of PKC  fused to
the NH2 terminus of GFP, Xpress-tagged PKC , and the luciferase reporter
gene plasmid driven by synthetic NFAT sites derived from the IL-2 pro-
moter have been described (Villalba et al., 2000a). An HA-tagged, domi-
nant negative PLC 1 mutant (PLCz) was a gift from Drs. Y. Abassi and K.
Vuori (the Burnham Institute, San Diego, CA). This plasmid encodes the
tandem SH2-SH2-SH3 domains of PLC 1 (Chen et al., 1996). A constitu-
tively active PI3-K plasmid (CD2p110) in the form of membrane targeted
PI3-K catalytic subunit (Reif et al., 1996) was provided by Dr. D. Cantrell
(Imperial cancer Research Fund, London, England). A c-Myc–tagged PDK1
construct (Chou et al., 1998) was provided by Dr. Toshi Kawakami (La
Jolla Institute for Allergy and Immunology, San Diego, CA). As control for
transfection efficiencies, a  -galactosidase ( -gal) expression plasmid in
the pEF vector was used (Villalba et al., 2000a).
Cell culture and transfection
Jurkat T cell lines were grown in RPMI-1640 medium (Life Technologies,
Inc.) supplemented with 10% fetal bovine serum, 2 mM glutamine, 1 mM
sodium pyruvate, 10 mM Hepes, MEM nonessential amino acid solution
(Life Technologies) and 100 U/ml each of penicillin G and streptomycin.
Cells in a logarithmic growth phase were transfected with the indicated
amounts of plasmid DNAs by electroporation as described (Villalba et al.,
1999, 2000a). Human peripheral blood mononuclear cells were prepared
from healthy volunteers by Ficoll-Hypaque centrifugation. Cells were stim-
ulated with an activating anti-CD3 mAb (OKT3; 1  g/ml) plus recombi-
nant human IL-2 (20 U/ml) for 5 d, and then deprived of OKT3 and IL-2
36 h prior to restimulation. Mouse T cells were obtained from lymph
nodes of Vav
 /  or normal littermate mice, and purified on mouse T cell
enrichment columns (R&D Systems). The cells were activated and rested
as above, except an anti–mouse CD3 mAb (2C11-145; 1  g/ml) was used.
Luciferase and  -gal assays
Transfected Jurkat-TAg cells were harvested after 2 d, washed twice with
PBS, and lysed. Luciferase or  -gal activities in cell extracts were deter-
mined as described (Villalba et al., 1999). The results are expressed as ar-
bitrary luciferase units per arbitrary  -gal units. All experiments were per-
formed in duplicate, and were repeated several times with similar results.
Subcellular fractionation
Subcellular fractionation of Jurkat T cells or peripheral blood mononuclear
cells was performed as previously described (Villalba et al., 2000a).
Briefly, Jurkat T cells were resuspended in ice-cold hypotonic lysis buffer,
and incubated on ice for 15 min. The cells were transferred to a 1-ml sy-
ringe, and sheared by passing them five times through a 30-gauge needle.
The lysates were centrifuged at 200 g for 10 min to remove nuclei and cell
debris, the supernatant was collected, and centrifuged at 13,000 g for 60
min at 4 C. The supernatant (cytosol) was collected, and the pellet was re-
suspended in lysis buffer, vortexed for 5 min at 4 C, and centrifuged again
at 13,000 g for 60 min at 4 C. The supernatant representing the particulate
(membrane) fraction was saved, and the detergent-insoluble fraction (cyto-
skeleton) was resuspended in 1% SDS in water. Each fraction was then di-
luted to with Laemmli buffer, and identical cell equivalents separated by
SDS-PAGE. The subcellular fractionation of activated human PBLs was
similar. However, due to their small size, cells were incubated in hypo-
tonic buffer lysis buffer in the presence of two drops of Polybead-polysty-
rene 4.5 micron microspheres (Polysciences, Inc.) with constant shaking in
order to facilitate their disruption. In some experiments (Fig. 3), fraction-
ation was not continued beyond isolation of the soluble (cytosol) and in-
soluble (membrane plus cytoskeleton) fractions in order to minimize de-
phosphorylation of PKC .
Purification of DIG fractions
Detergent-insoluble and soluble fractions were separated as described pre-
viously (Zhang et al., 1998; Bi et al., 2001) with some modifications.
Briefly, Jurkat T cells (20   10
6) were lysed in 1 ml MNE buffer (25 mM
MES, pH 6.5, 150 mM NaCl, 5 mM EDTA, 30 mM sodium pyrophosphate,
1 mM sodium orthovanadate and 10  g/ml protease inhibitors) containing
1% Triton X-100 for 20 min on ice and dounced 15 times. Samples were
centrifuged at 1,000 g for 10 min at 4 C. The supernatants were then
mixed with 1 ml 80% sucrose and transferred to Beckman ultracentrifuge
tubes. 2 ml of 30% sucrose followed by 1 ml of 5% sucrose in MNE buffer
were overlaid. Samples were subjected to ultracentrifugation (200,000 g)
for 18 h at 4 C in a Beckman SW50Ti rotor. 12 fractions were collected
from the top of the gradient. Proteins from each fraction were TCA precipi-
tated before separation by 10% SDS-PAGE.
Immunofluorescence and confocal microscopy
Jurkat cells were incubated with or without 1  g/ml each of anti-CD3 and
anti-CD28 mAbs for 10 min over poly-L-lysine–treated microscope slides
at 37 C. Cells were then fixed for 20 min with 3.7% paraformaldehyde at
room temperature, permeabilized for 2 min with 0.1% Triton X-100 in
PBS, blocked for 15 min with 1% BSA in PBS, and then stained with phal-
loidin-TRITC (Sigma-Aldrich) for 30 min. After washing four times with 1%
BSA in PBS, the cells were mounted using a drop of Aqua-Poly/mount
(Polysciences). Samples were viewed with a Plan-Apochromat 63  lens
on a Nikon microscope. Images were taken using BIORAD MRC 1024 la-
ser scanning confocal imaging system.
Activated mouse T cells were similarly incubated over poly-L-lysine–
treated microscope slides coated or not with 5  g/ml of anti–mouse-CD3
plus-CD28 antibodies in Tris 50 mM, pH 9, for 1 h at 37 C, followed by
4 h at 4  C. Cells were then fixed and permeabilized as described above,
and stained with a polyclonal anti-PKC  antibody (C-18) for 1 h. The cells
were washed with 1% BSA in PBS, and then incubated with a secondary
sheep anti–mouse IgG antibody coupled with Alexa 594 (Molecular Probes)
plus phalloidin-FITC. The cells were subsequently washed and processed for
confocal microscopy as described above. Microsoft PowerPoint software
was used to prepare digital images of gel scans and micrographs.
We would like to thank Drs. Y. Abassi, D. Cantrell, M. Croft, T. Kawakami,
A. Toker, V. Tybulewicz and K. Vuori, for mice and plasmids, and N.
Weaver for manuscript preparation. 
This work was supported by National Institutes of Health Grants
CA35299 and GM50819 (A. Altman). M. Villalba is a Special Fellow of the
Leukemia & Lymphoma Society (formerly The Leukemia Society of Amer-
ica, Inc). This is publication number 426 from the La Jolla Institute for Al-
lergy and Immunology, San Diego, CA.
Submitted: 22 January 2002
Accepted: 1 March 2002
References
Aghazadeh, B., W.E. Lowry, X.-Y. Huang, and M.K. Rosen. 2000. Structural basis
for the relief of autoinhibition of the Dbl homology domain of proto-onco-
gene Vav by tyrosine phosphorylation. Cell. 102:625–633.
Altman, A., T. Mustelin, and K.M. Coggeshall. 1990. T lymphocyte activation: a
biological model of signal transduction. Crit. Rev. Immunol. 10:347–391.
Altman, A., N. Isakov, and G. Baier. 2000. PKC : a new essential superstar on the
T cell stage. Immunol. Today. 21:567–573.
Baier, G., D. Telford, L. Giampa, K.M. Coggeshall, G. Baier-Bitterlich, N. Isakov,
and A. Altman. 1993. Molecular cloning and characterization of PKC , a
human novel member of the protein kinase C (PKC) gene family expressed
predominantly in hematopoietic cells. J. Biol. Chem. 268:4997–5004.
Baier-Bitterlich, G., F. Überall, B. Bauer, F. Fresser, H. Wachter, H. Grünicke, G.
Utermann, A. Altman, and G. Baier. 1996. PKC  isoenzyme selective stim-
ulation of the transcription factor complex AP-1 in T lymphocytes. Mol.
Cell. Biol. 16:1842–1850.
Balendran, A., G.R. Hare, A. Kieloch, M.R. Williams, and D.R. Alessi. 2000. Fur-
ther evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1)
is required for the stability and phosphorylation of protein kinase C (PKC)
isoforms. FEBS Lett. 484:217–223.
Bauer, B., N. Krumbök, F. Fresser, F. Hochholdinger, M. Spitaler, W. Schwaiger,
A. Simm, F. Überall, B. Schraven, and G. Baier. 2001. Complex formation
and cooperation of PKC  and Akt1/PKB  in the transactivation of the
IKK /I- B -/NF- B signaling cascade in T cells. J. Biol. Chem. 276:
31627–31634.
Bi, K., Y. Tanaka, N. Coudronniere, S. Hong, K. Sugie, M.J.B. van Stipdonk, and
A. Altman. 2001. Antigen-induced translocation of PKC-  to membrane
rafts is required for T cell activation. Nat. Immunol. 2:556–563.
Bustelo, X.R. 2000. Regulatory and signaling properties of the Vav family. Mol.
Cell. Biol. 20:1461–1477.
Chen, P., H. Xie, and A. Wells. 1996. Mitogenic signaling from the EGF receptor
is attenuated by a phospholipase C- /protein kinase C feedback mechanism.
Mol. Biol. Cell. 7:871–881.
Chou, M.M., W. Hou, J. Johnson, L.K. Graham, M.H. Lee, C.S. Chen, A.C.
Newton, B.S. Schaffhausen, and A. Toker. 1998. Regulation of protein ki-262 The Journal of Cell Biology | Volume 157, Number 2, 2002
nase C zeta by PI 3-kinase and PDK-1. Curr. Biol. 8:1069–1077.
Collins, T., M. Deckert, and A. Altman. 1997. Views on Vav. Immunol. Today. 18:
221–225.
Costello, P.S., A.E. Walters, P.J. Mee, M. Turner, L.F. Reynolds, A. Prisco, N.
Sarner, R. Zamoyska, and V.L.J. Tybulewicz. 1999. The Rho-family GTP
exchange factor Vav is a critical transducer of T cell receptor signals to the
calcium, ERK, and NF- B pathways. Proc. Natl. Acad. Sci. USA. 96:3035–
3040.
Coudronniere, N., M. Villalba, N. Englund, and A. Altman. 2000. NF- B activa-
tion induced by CD28 costimulation is mediated by PKC . Proc. Natl.
Acad. Sci. USA. 97:3394–3399.
Dienz, O., S.P. Hehner, W. Droge, and M.L. Schmitz. 2000. Synergistic activation
of NF- B by functional cooperation between vav and PKC  in T lympho-
cytes. J. Biol. Chem. 275:24547–24551.
Dutil, E.M., and A.C. Newton. 2000. Dual role of pseudosubstrate in the coordi-
nated regulation of protein kinase C by phosphorylation and diacylglycerol.
J. Biol. Chem. 275:10697–10701.
Dutil, E.M., A. Toker, and A.C. Newton. 1998. Regulation of conventional pro-
tein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1).
Curr. Biol. 8:1366–1375.
Fischer, K.D., Y.Y. Kong, H. Nishina, K. Tedford, L.E. Marengère, I. Kozieradzki,
T. Sasaki, M. Starr, G. Chan, S. Gardener, et al. 1998. Vav is a regulator of
cytoskeletal reorganization mediated by the T-cell receptor. Curr. Biol.
8:554–562.
Gao, T., A. Toker, and A.C. Newton. 2001. The carboxyl terminus of protein ki-
nase c provides a switch to regulate its interaction with the phosphoinosi-
tide-dependent kinase, PDK-1. J. Biol. Chem. 276:19588–19596.
Grakoui, A., S.K. Bromley, C. Sumen, M.M. Davis, A.S. Shaw, P.M. Allen, and
M.L. Dustin. 1999. The immunological synapse: a molecular machine con-
trolling T cell activation. Science. 285:221–227.
Granja, C., L.-L. Lin, E.J. Yunis, V. Relias, and J.D. Dasgupta. 1991. PLC 1, a
possible mediator of T cell receptor function. J. Biol. Chem. 266:16277–
16280.
Han, J., K. Luby Phelps, B. Das, X. Shu, Y. Xia, R.D. Mosteller, U.M. Krishna,
J.R. Falck, M.A. White, and D. Broek. 1998. Role of substrates and prod-
ucts of PI 3-kinase in regulating activation of Rac-related guanosine triphos-
phatases by Vav. Science. 279:558–560.
Hehner, S.P., M. Li-Weber, M. Giaisi, W. Droge, P.H. Krammer, and M.L.
Schmitz. 2000. Vav synergizes with protein kinase Cq to mediate IL-4 gene
expression in response to CD28 costimulation in T cells. J. Immunol. 164:
3829–3836.
Holsinger, L.J., I.A. Graef, W. Swat, T. Chi, D.M. Bautista, L. Davidson, R.S.
Lewis, F.W. Alt, and G.R. Crabtree. 1998. Defects in actin-cap formation in
Vav-deficient mice implicate an actin requirement for lymphocyte signal
transduction. Curr. Biol. 8:563–572.
Irvin, B.J., B.L. Williams, A.E. Nilson, H.O. Maynor, and R.T. Abraham. 2000.
Pleiotropic contributions of phospholipase C- 1 to T-cell antigen receptor-
mediated signaling: reconstitution studies of a PLC- 1-deficient Jurkat
T-cell line. Mol. Cell. Biol. 20:9149–9161.
Isakov, N., and A. Altman. 2002. PKC  in T cell activation. Annu. Rev. Immunol.
20:761–794.
Kane, L.P., J. Lin, and A. Weiss. 2000. Signal transduction by the TCR for anti-
gen. Curr. Opin. Immunol. 12:242–249.
Keranen, L.M., E.M. Dutil, and A.C. Newton. 1995. Protein kinase C is regulated
in vivo by three functionally distinct phosphorylations. Curr. Biol. 5:1394–
1403.
Krawczyk, C., K. Bachmaier, T. Sasaki, R.G. Jones, S.B. Snapper, D. Bouchard, I.
Kozieradzki, P.S. Ohashi, F.W. Alt, and J.M. Penninger. 2000. Cbl-b is a
negative regulator of receptor clustering and raft aggregation in T cells. Im-
munity. 13:463–473.
Le Good, J.A., W.H. Ziegler, D.B. Parekh, D.R. Alessi, P. Cohen, and P.J. Parker.
1998. Protein kinase C isotypes controlled by phosphoinositide 3-kinase
through the protein kinase PDK1. Science. 281:2042–2045.
Lin, X., A. O’Mahony, R. Geleziunas, and W.C. Greene. 2000. Protein kinase C  
participates in NF- B/Rel activation induced by CD3/CD28 costimulation
through selective activation of I B   (IKK ). Mol. Cell. Biol. 20:2933–
2940.
Liu, Y., C. Graham, A. Li, R.J. Fisher, and S. Shaw. 2002. Phosphorylation of the
protein kinase C-  activation loop and hydrophobic motif regulates its ki-
nase activity, but only activation loop phosphorylation is critical to in vivo
nuclear-factor- B induction. Biochem. J. 361:255–265.
Medkova, M., and W. Cho. 1999. Interplay of C1 and C2 domains of protein ki-
nase C-  in its membrane binding and activation. J. Biol. Chem. 274:
19852–19861.
Moller, A., O. Dienz, S.P. Hehner, W. Droge, and M.L. Schmitz. 2001. PKC- 
cooperates with Vav1 to induce JNK activity in T-cells. J. Biol. Chem. 276:
20022–20028.
Monks, C.R.F., H. Kupfer, I. Tamir, A. Barlow, and A. Kupfer. 1997. Selective
modulation of protein kinase C-  during T-cell activation. Nature. 385:83–
86.
Monks, C.R., B.A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer. 1998. Three-
dimensional segregation of supramolecular clusters in T cells. Nature. 395:
82–86.
Newton, A.C. 1997. Regulation of protein kinase C. Curr. Opin. Cell Biol. 9:161–
167.
Nishizuka, Y. 1995. Protein kinase C and lipid signaling for sustained cellular re-
sponses. FASEB J. 9:484–496.
Parekh, D., W. Ziegler, K. Yonezawa, K. Hara, and P.J. Parker. 1999. Mammalian
TOR controls one of two kinase pathways acting upon nPKC  and nPKC .
J. Biol. Chem. 274:34758–34764.
Parekh, D.B., W. Ziegler, and P.J. Parker. 2000. Multiple pathways control pro-
tein kinase C phosphorylation. EMBO J. 19:496–503.
Park, D.J., H.W. Rho, and S.G. Rhee. 1991. CD3 stimulation causes phosphoryla-
tion of phospholipase C 1 on serine and tyrosine residues in a T cell line.
Proc. Natl. Acad. Sci. USA. 88:5453–5456.
Reif, K., C.D. Nobes, G. Thomas, A. Hall, and D.A. Cantrell. 1996. Phosphati-
dylinositol 3-kinase signals activate a selective subset of Rac/Rho-dependent
effector pathways. Currr Biol. 6:1445–1455.
Rozelle, A.L., L.M. Machesky, M. Yamamoto, M.H. Driessens, R.H. Insall, M.G.
Roth, K. Luby-Phelps, G. Marriott, A. Hall, and H.L. Yin. 2000. Phos-
phatidylinositol 4,5-bisphosphate induces actin-based movement of raft-en-
riched vesicles through WASP-Arp2/3. Curr. Biol. 10:311–320.
Rudd, C.E. 1996. Upstream-downstream: CD28 cosignaling pathways and T cell
function. Immunity. 4:527–534.
Secrist, J.P., L. Karnitz, and R.T. Abraham. 1991. T cell antigen receptor ligation
induces tyrosine phosphorylation of phospholipase C 1. J. Biol. Chem. 266:
12135–12139.
Sonnenburg, E.D., T. Gao, and A.C. Newton. 2001. The phosphoinositide-
dependent kinase, PDK-1, phosphorylates conventional protein kinase C
isozymes by a mechanism that is independent of phosphoinositide 3-kinase.
J. Biol. Chem. 276:45289–45297.
Sun, Z., C.W. Arendt, W. Ellmeier, E.M. Schaeffer, M.J. Sunshine, L. Gandhi, J.
Annes, D. Petrzilka, A. Kupfer, P.L. Schwartzberg, and D.R. Littman. 2000.
PKC-  is required for TCR-induced NF- B activation in mature but not
immature T lymphocytes. Nature. 404:402–407.
Szallasi, Z., K. Bogi, S. Gohari, T. Biro, P. Acs, and P.M. Blumberg. 1996. Non-
equivalent roles for the first and second zinc fingers of protein kinase Cdelta.
Effect of their mutation on phorbol ester-induced translocation in NIH 3T3
cells. J Biol Chem. 271:18299–18301.
Toker, A., and A.C. Newton. 2000. Cellular signaling: pivoting around PDK-1.
Cell. 103:185–188.
Turner, M., P.J. Mee, A.E. Walters, M.E. Quinn, A.L. Mellor, R. Zamoyska, and
V.L.J. Tybulewicz. 1997. A requirement for the Rho-family GTP exchange
factor Vav in positive and negative selection of thymocytes. Immunity.
7:451–460.
van Leeuwen, J.E., and L.E. Samelson. 1999. T cell antigen-receptor signal trans-
duction. Curr. Opin. Immunol. 11:242–248.
Vassilopoulos, D., R.C. Smallridge, and G.C. Tsokos. 1995. Effects of an amino-
steroid inhibitor of phospholipase C-dependent processes on the TCR-
mediated signal transduction pathway in human T cells. Clin. Immunol. Im-
munopathol. 77:59–68.
Villalba, M., S. Kasibhatla, L. Genestier, A. Mahboubi, D.R. Green, and A. Alt-
man. 1999. PKC  is a necessary component, and cooperates with cal-
cineurin, to induce FasL expression during activation-induced T cell death.
J. Immunol. 163:5813–5819.
Villalba, M., N. Coudronniere, M. Deckert, E. Teixeiro, P. Mas, and A. Altman.
2000a. Functional interactions between Vav and PKC  are required for
TCR-induced T cell activation. Immunity. 12:151–160.
Villalba, M., J. Hernandez, M. Deckert, and A. Altman. 2000b. Vav modulation of
the Ras/MEK/ERK signaling pathway plays a role in NFAT activation and
CD69 upregulation. Eur. J. Immunol. 30:1587–1596.
Villalba, M., K. Bi, F. Rodriguez, Y. Tanaka, S. Schoenberger, and A. Altman.
2001. Vav1/Rac-dependent actin cytoskeleton reorganization is required for
lipid raft clustering in T cells. J. Cell Biol. 155:331–338.Vav/PI3-K–dependent PKC  activation in T cells | Villalba et al. 263
Wang, X.D., J.G. Kiang, and R.C. Smallridge. 1994. A phospholipase C inhibitor,
U73122, blocks TSH-induced inositol trisphophate production Ca
2 -
increase and arachidonic acid release in FRTL-5 thyroid cells. Biochim. Bio-
phys. Acta. 1223:101–108.
Weiss, A., G. Koretzky, R.C. Schatzman, and T. Kadlecek. 1991. Functional acti-
vation of the T-cell antigen receptor induces tyrosine phosphorylation of
phospholipase C-  1. Proc. Natl. Acad. Sci. USA. 88:5484–5488.
Wülfing, C., A. Bauch, G.R. Crabtree, and M.M. Davis. 2000. The vav exchange
factor is an essential regulator in actin-dependent receptor translocation to
the lymphocyte-antigen-presenting cell interface. Proc. Natl. Acad. Sci. USA.
97:10150–10155.
Zhang, W., R.P. Trible, and L.E. Samelson. 1998. LAT palmitoylation: its essen-
tial role in membrane microdomain targeting and tyrosine phosphorylation
during T cell activation. Immunity. 9:239–246.
Zhang, W., R.P. Trible, M. Zhu, S.K. Liu, C.J. McGlade, and L.E. Samelson.
2000. Association of Grb2, Gads, and phospholipase C-  1 with phosphory-
lated LAT tyrosine residues. Effect of LAT tyrosine mutations on T cell anti-
gen receptor-mediated signaling. J. Biol. Chem. 275:23355–23361.
Ziegler, W.H., D.B. Parekh, J.A. Le Good, R.D. Whelan, J.J. Kelly, M. Frech,
B.A. Hemmings, and P.J. Parker. 1999. Rapamycin-sensitive phosphoryla-
tion of PKC on a carboxy-terminal site by an atypical PKC complex. Curr.
Biol. 9:522–529.264 The Journal of Cell Biology | Volume 157, Number 2, 2002